A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-21

Study Completion Date

2023-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess safety and tolerability of prostacyclin receptor agonist formulation in treatment period 1 and with different formulation of prostacyclin receptor agonist in treatment period 2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742

Pulmonary Arterial Hypertension

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

NCT05135000

Pulmonary Arterial Hypertension

TERMINATED PHASE2

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT05649722

Pulmonary Hypertension Interstitial Lung Disease

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

NCT05764265

Pulmonary Arterial Hypertension

TERMINATED PHASE2

A Study to Evaluate GSK1325760A - a Long-Term Extension Study

NCT00554619

Pulmonary Arterial Hypertension Hypertension, Pulmonary

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prostacyclin Receptor Agonist

Participants in Cohort 1-7 will receive multiple doses of prostacyclin receptor agonist of formulation 1 in treatment period 1, followed by a single dose of various other formulations (formulation 2, 3, and 4) in treatment period 2. Cohort 7 will be optional. Doses in Cohorts 4, 5, 6 and cohort 7 will be based on PK, safety and tolerability data of previous 3 cohorts (preceding cohorts).

Group Type EXPERIMENTAL

Prostacyclin Receptor Agonist

Intervention Type DRUG

Prostacyclin receptor agonist will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prostacyclin Receptor Agonist

Prostacyclin receptor agonist will be administered.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Otherwise, healthy as deemed by the investigator on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiograms (ECG) performed at Screening and Day -1 of oral treatment period
* Otherwise, healthy medically stable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, blood coagulation, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
* Body mass index (BMI) within the range 18.0 to 32.0 kilograms per meter square (kg/m\^2) (inclusive) and body weight not less than 50 kilograms (kg) at screening
* All female participants must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[beta-hCG\]) at screening
* A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study intervention

Exclusion Criteria

* Known allergies, hypersensitivity, anaphylaxis, or intolerance to prostacyclin receptor agonist or drugs of the same class, or any excipient (including poloxamer and polysorbate) of the drug formulation(s)
* Clinically significant abnormal physical examination, vital signs, or 12-lead ECG (QTc greater than or equal to \[\>=\]450 milliseconds \[msec\] for men and \>=460 msec for women. QT corrected according to Bazett's formula \[QTcB\]) as assessed by the Investigator at Screening or Day -1 of oral treatment period
* History of malignancy within 3 years before screening (exceptions are squamous and basal cell carcinomas of the skin
* Positive serologic testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (hBsAg), hepatitis C virus (HCV), active coronavirus disease 2019 (COVID-19) infection
* A history of repeated (more than once over the last 30 days) fainting due to cardiac cause, collapse, syncope, orthostatic hypotension, or vasovagal reactions

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes